Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Assisted Reproduction and Genetics
Published in: Journal of Assisted Reproduction and Genetics 3/2024

22-01-2024 | GnRH Agonists | Commentary

LH supplementation in IVF: human nature, politics, and elephants in the room

Authors: Juan Castillo, Alexander M. Quaas, Shahar Kol

Published in: Journal of Assisted Reproduction and Genetics | Issue 3/2024

Login to get access

Abstract

Luteinizing hormone (LH) is present throughout the natural follicular phase. However, the debate is still not settled on whether LH is needed during ovarian stimulation in IVF. This commentary looks at the evolution of this debate, mentioning three elephants in the room that were ignored by the Pharma industry, professional organizations, and clinicians alike:
1.
The different endocrinology between the long agonist and the antagonist protocols.
 
2.
The fixed dose of the two most widely commercially available antagonist preparations, namely cetrorelix and ganirelix.
 
3.
The fact that most research in this area uses population-based criteria, ignoring endocrine parameters.
 
Individual genetics of the LH receptor gene may also serve to individualize LH needs during stimulation; however, the jury is still out regarding this approach.

Conclusions

Individual endocrine and genetics parameters may shed meaningful light on the question of LH supplemental during ovarian stimulation.
Literature
1.
Peñarrubia J, Fábregues F, Creus M, Manau D, Casamitjana R, Guimerá M, et al. LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. Hum Reprod Oxf Engl. 2003;18:2689–97.CrossRef
2.
A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod Oxf Engl. 1998;13:3023–31.
3.
Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod Oxf Engl. 2000;15:1490–8.CrossRef
4.
5.
Bonczar M, Wysiadecki G, Ostrowski P, Michalczak M, Plutecki D, Wilk J, et al. The morphology of the pituitary gland: a meta-analysis with implications for diagnostic imaging. Brain Sci. 2023;13:89.CrossRefPubMedPubMedCentral
6.
Laporte E, Vennekens A, Vankelecom H. Pituitary remodeling throughout life: are resident stem cells involved? Front Endocrinol. 2020;11:604519.CrossRef
7.
Ovarian Stimulation TEGGO, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Hum Reprod Open. 2020;2020:hoaa009.CrossRefPubMed
8.
European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab. 2001;86:2607–18.
9.
Bosch E, Alviggi C, Lispi M, Conforti A, Hanyaloglu AC, Chuderland D, et al. Reduced FSH and LH action: implications for medically assisted reproduction. Hum Reprod Oxf Engl. 2021;36:1469–80.CrossRef
10.
Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online. 2004;8:175–82.CrossRefPubMed
11.
Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online. 2004;8:635–43.CrossRefPubMed
12.
Fábregues F, Creus M, Peñarrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril. 2006;85:925–31.CrossRefPubMed
13.
Fábregues F, Iraola A, Casals G, Creus M, Carmona F, Balasch J. Evaluation of two doses of recombinant human luteinizing hormone supplementation in down-regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. Eur J Obstet Gynecol Reprod Biol. 2011;158:56–61.CrossRefPubMed
14.
NyboeAndersen A, Humaidan P, Fried G, Hausken J, Antila L, Bangsbøll S, et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod Oxf Engl. 2008;23:427–34.CrossRef
15.
Barrenetxea G, Agirregoikoa JA, Jiménez MR, de Larruzea AL, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril. 2008;89:546–53.CrossRefPubMed
16.
Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P, et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online. 2009;19:879–87.CrossRefPubMed
17.
Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2011;95:1031–6.CrossRefPubMed
18.
König TE, van der Houwen LEE, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchenbecker WKH, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod Oxf Engl. 2013;28:2804–12.CrossRef
19.
Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Hum Reprod Oxf Engl. 2015;30:1188–95.CrossRef
20.
Younis JS, Izhaki I, Ben-Ami M. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study. Clin Endocrinol (Oxf). 2016;84:99–106.CrossRefPubMed
21.
Conforti A, Esteves SC, Humaidan P, Longobardi S, D’Hooghe T, Orvieto R, et al. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol RBE. 2021;19:91.CrossRef
22.
Alviggi C, Pettersson K, Longobardi S, Andersen CY, Conforti A, De Rosa P, et al. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol RBE. 2013;11:51.CrossRef
23.
Ga R, Cheemakurthi R, Kalagara M, Prathigudupu K, Balabomma KL, Mahapatro P, et al. Effect of LHCGR gene polymorphism (rs2293275) on LH supplementation protocol outcomes in second IVF cycles: a retrospective study. Front Endocrinol. 2021;12:628169.CrossRef
24.
Altmäe S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011;17:813–28.CrossRefPubMed
Metadata
Title
LH supplementation in IVF: human nature, politics, and elephants in the room
Authors
Juan Castillo
Alexander M. Quaas
Shahar Kol
Publication date
22-01-2024
Publisher
Springer US
Keyword
GnRH Agonists
Published in
Journal of Assisted Reproduction and Genetics / Issue 3/2024
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-024-03033-9

Other articles of this Issue 3/2024

Journal of Assisted Reproduction and Genetics 3/2024 Go to the issue

Assisted Reproduction Technologies

Mosaic embryo transfer versus additional IVF with PGT-A Cycle: a decision model comparing live birth rate and cost

Genetics

Y chromosome polymorphisms contribute to an increased risk of non-obstructive azoospermia: a retrospective study of 32,055 Chinese men

Review

Do IVF culture conditions have an impact on neonatal outcomes? A systematic review and meta-analysis

Genetics

Extended application of PGT-M strategies for small pathogenic CNVs

Genetics

A report of two homozygous TERB1 protein-truncating variants in two unrelated women with primary infertility

Assisted Reproduction Technologies

Ultrasound evaluation of the cardiovascular system in offspring conceived through assisted reproductive technology